George Poste has sold EXEL and made no open-market buys since Mar 2017

George Poste, DVM, Ph.D., FRS

Director, Exelixis, Inc.

George Poste, DVM, Ph.D., FRS, has served as a director at Exelixis, Inc., a genomics-based drug discovery company, since August 2004.( He is currently the Chief Scientist at the Complex Adaptive Systems Initiative and Regents’ Professor and Del E. Webb Professor of Health Innovation at Arizona State University (since 2009), and Chief Executive Officer of Health Technology Networks, a consulting firm specializing in genomic technologies and computing in healthcare (since 2000).( Previously, he directed the Biodesign Institute at Arizona State University (2003-2009) and was Chief Science and Technology Officer and President of R&D at SmithKline Beecham Corporation (1992-1999), overseeing the registration of 31 drug, vaccine, and diagnostic products.(

Dr. Poste has held board positions at Caris Life Sciences (since 2009), InanoBio, Inc. (since 2021), and MediSix Therapeutics Pte. Ltd. (since 2022), and previously at Monsanto Company (2003-2018) and Orchid Cellmark, Inc. (2000-2009).( He served on the U.S. Department of Defense's Defense Science Board (2001-2010), focusing on bioweapons defense.( Education includes a DVM from the University of Bristol (1966, first in class).(

Written by Perplexity from public sources.